Publications by authors named "David Eichenbaum"

Claim this Profile
I
Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.
Jean-François Korobelnik, Paolo Lanzetta, Sergio Leal, Frank G Holz, W Lloyd Clark, David Eichenbaum

Ophthalmology· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study.
Nasiq Hasan, Elham Sadeghi, Luiz H Lima, Jay C Wang, Rahul N Khurana, David Eichenbaum

Graefes Arch Clin Exp Ophthalmol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Intravitreal Pegcetacoplan vs Avacincaptad Pegol in Patients With Geographic Atrophy.
Paul Hahn, David Eichenbaum, Dilsher S Dhoot, Charles C Wykoff, Michael A Klufas

J Vitreoretin Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degeneration.
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, Sergio Leal, Frank G Holz, David Eichenbaum

Ther Adv Ophthalmol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Comment on Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
David A Eichenbaum, Nancy Holekamp, Arshad M Khanani, Dante Pieramici, Vrinda Hershberger

Am J Ophthalmol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
David A Eichenbaum, Nancy Holekamp, Arshad M Khanani, Dante Pieramici, Vrinda Hershberger

Am J Ophthalmol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RWC Update: Intraocular Inflammation and Retinal Pharmacotherapy; Giant Retinal Tear; ILM Peeling in Myopic Macular Schisis.
Ashish Sharma, Lihteh Wu, Steven Bloom, Paulo Stanga, David A Eichenbaum

Ophthalmic Surg Lasers Imaging Retina· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endophthalmitis in Eyes Treated with the Port Delivery System with Ranibizumab: Summary of Cases during Clinical Trial Development.
David A Eichenbaum, William R Freeman, Margaret A Chang, Logan Brooks, Nauman Chaudhry

Ophthalmol Retina· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration.
Peter A Campochiaro, David Eichenbaum, Margaret A Chang, W Lloyd Clark, Jordan M Graff

Ophthalmol Retina· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series.
Deepak Sambhara, Priya Vakharia, David A Eichenbaum

BMJ Open Ophthalmol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study.
Ashish Sharma, Frank G Holz, Nilesh Kumar, David Sarraf, Seemantini Ayachit, David Eichenbaum

J Vitreoretin Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screen Failures in Clinical Trials in Retina.
Nasiq Hasan, Kunaal Mehrotra, Carl J Danzig, David A Eichenbaum, Amy Ewald

Ophthalmol Retina· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Consensus Guideline for the Diagnosis and Management of Chronic Noninfectious Uveitis Affecting the Posterior Segment.
Rishi P Singh, Thomas A Albini, Caroline R Baumal, Peter Y Chang, David Eichenbaum

Ophthalmic Surg Lasers Imaging Retina· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluocinolone acetonide 0.18-mg implant for treatment of recurrent inflammation due to non-infectious uveitis: a case series of 15 patients.
Robert A Sisk, Daniel F Kiernan, David Almeida, Anton M Kolomeyer, David Eichenbaum

J Ophthalmic Inflamm Infect· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices.
Sabin Dang, D Wilkin Parke, Guneet S Sodhi, David Eichenbaum, Jared Nielsen

JAMA Ophthalmol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review.
Ian M Leitch, Michael Gerometta, David Eichenbaum, Robert P Finger, Nathan C Steinle

Ophthalmol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RWC Update: Removal of Subretinal Band Without Retinotomy; Geographic Atrophy: How Do You Select Appropriate Patients for Anti-Complement Therapy?; Shaken Baby Syndrome.
Ashish Sharma, Lihteh Wu, Steven Bloom, Paulo Stanga, Nassim Abreu, David Eichenbaum

Ophthalmic Surg Lasers Imaging Retina· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic atrophy: current and future therapeutic agents and practical considerations for retinal specialists.
Priya Vakharia, David Eichenbaum

Curr Opin Ophthalmol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration.
Sunil Patel, Philip P Storey, Mark R Barakat, Vrinda Hershberger, William Z Bridges, David A Eichenbaum

Ophthalmol Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.
Paolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, Sergio Leal, Frank G Holz, David Eichenbaum

Lancet· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
Daniel B Roth, David Eichenbaum, Deepika Malik, Nathan M Radcliffe, Antonio Cutino

Ophthalmol Retina· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular, Visual, and Anatomical Outcomes in Eyes Requiring Incisional Intraocular Pressure-Lowering Surgery Following the 0.19-mg Fluocinolone Acetonide Intravitreal Implant.
David Eichenbaum, Victor H Gonzalez, Daniel Roth, Jorge Fortun, Nathan M Radcliffe

Ophthalmic Surg Lasers Imaging Retina· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.
Sunil S Patel, David R Lally, Jason Hsu, Charles C Wykoff, David Eichenbaum

Eye (Lond)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
Rishi P Singh, Mark R Barakat, Michael S Ip, Charles C Wykoff, David A Eichenbaum

JAMA Ophthalmol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial.
Arshad M Khanani, Sunil S Patel, Giovanni Staurenghi, Ramin Tadayoni, Carl J Danzig, David A Eichenbaum

Lancet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis